Loading clinical trials...
Loading clinical trials...
A Single-arm, Open-label, Multicenter, Phase II Clinical Trials of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）
Conditions
Interventions
TQ-B3525 tablets
Locations
2
China
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Beijing Hospital
Beijing, Beijing Municipality, China
Start Date
January 20, 2021
Primary Completion Date
March 31, 2022
Completion Date
June 30, 2022
Last Updated
August 18, 2021
NCT05139017
NCT01804686
NCT05755087
NCT04739813
NCT06785818
NCT06043011
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions